Compare Ascendis Pharma A/S (ASND) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Texas Instruments Incorporated — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Texas Instruments Incorporated trades at $306.52 (market cap $283.46B). The key difference: Texas Instruments Incorporated is far larger — about 16× Ascendis Pharma A/S's market cap, and Texas Instruments Incorporated pays a 1.82% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TXN | |
|---|---|---|
Market Cap | $17.74B | $283.46B |
Sector | Health | Technology |
52-Week High | $277.18 | $332.35 |
52-Week Low | $163.32 | $153.33 |
Enterprise Value | $18.11B | $292.40B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Texas Instruments (TXN) trades at $311.51, up 0.94% today, showing strong technical momentum with a bullish moving average signal. The company reported mixed Q1 2026 earnings, beating expectations with $1.68 EPS versus $1.36 expected, while Q3 and Q4 2025 missed. Recent CFO transition to Julie Knecht signals stable leadership. Revenue grew to $17.68B in 2025 from $15.6B in 2024, with net income margin at 29.11%.
Outlook remains positive with 65 analysts showing 48% buy rating and $310.95 consensus target. Key risks include high valuation multiples (P/E 53.24) and rising debt-to-asset ratio (40.61% in 2025). AI-driven data center demand presents growth opportunity, but competition and macroeconomic pressures warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
